Botulinum toxin clinical uses

Botulinum toxin clinical uses are condition- and treatment-goal entry points. They help readers move from a real-world question, such as migraine, cervical dystonia, sweating, frown lines, or masseter prominence, toward the products, toxin types, anatomy, labels, and safety context that make the question interpretable.

Approval context

An indication page is not an approval table. Approved uses differ by product and region, and common clinical discussion does not make a use approved for every product. The U.S. FDA indication matrix summarizes current U.S. labeled indications, while the U.S. FDA approval timeline collects major FDA anchors for current U.S.-visible brands.

Clinical Use Directory

Use context	Treatment goal or target	Status question to check first
Chronic migraine	Preventive headache care	Which product and population are covered by the local therapeutic label?
Cervical dystonia	Neck posture, pain, and movement control	Which type A or type B product, label, and unit system are being discussed?
Blepharospasm	Functional control of involuntary eyelid closure	Does the product label cover the disorder, patient age, and market?
Hemifacial spasm	Control of involuntary unilateral facial movement	Is the claim an explicit product indication or a clinical-use evidence claim?
Hyperhidrosis	Reduction of excessive sweating	Which body site and patient population does the product label cover?
Limb spasticity	Goal-directed reduction of muscle overactivity	Are adult and pediatric, upper- and lower-limb, and product-specific scopes separated?
Glabellar lines	Temporary improvement of dynamic frown lines	Which aesthetic product, named facial area, and regional label apply?
Crow’s feet	Temporary improvement of lateral canthal lines	Is the named area included in the product’s local aesthetic label?
Masseter hypertrophy	Muscle-volume reduction, contouring, or a distinct functional question	Is this approved use, region-specific use, or evidence for an unapproved context?

Approved Indications and Clinical Use Contexts

An approved indication is a regulator- and product-specific claim. A clinical use context is broader: it may include published research, common practice, regional approvals, or unapproved use. The two categories overlap, but they are not interchangeable.

A condition associated with several products in research or practice does not give those products the same approval, dose language, formulation, unit system, warning language, or regional availability. Each page therefore separates the condition or treatment goal from the product-and-market status used to support a claim.

Relationship Map

Question	Best next page
Which products are visible in the current U.S.-oriented brand graph?	Botulinum toxin brands
Which represented products have current U.S. labeled indications?	U.S. FDA indication matrix
Why are type A and type B not the same comparison group?	Type A vs type B
Why can units not be converted across brands?	Unit interpretation
Why does anatomy change safety and spread interpretation?	How anatomy changes botulinum toxin interpretation
Which companies sit behind major products?	Botulinum toxin companies

Coverage Boundaries

These pages avoid treatment instructions, dosing tables, and universal brand recommendations. They summarize the relationship between a use context and the current knowledge graph. Product-specific labels and regional regulatory records remain the authority for approved indications, warnings, preparation, and dosing language.

References

• DailyMed: BOTOX prescribing information 🔗
• Botulinum Toxin - StatPearls, NCBI Bookshelf 🔗